» Articles » PMID: 36428508

How the Tumor Micromilieu Modulates the Recruitment and Activation of Colorectal Cancer-Infiltrating Lymphocytes

Overview
Journal Biomedicines
Date 2022 Nov 26
PMID 36428508
Authors
Affiliations
Soon will be listed here.
Abstract

The successful treatment of advanced colorectal cancer disease still represents an insufficiently solved clinical challenge, which is further complicated by the fact that the majority of malignant colon tumors show only relatively low immunogenicity and therefore have only limited responsiveness to immunotherapeutic approaches, such as, for instance, the use of checkpoint inhibitors. As it has been well established over the past two decades that the local tumor microenvironment and, in particular, the quantity, quality, and activation status of intratumoral immune cells critically influence the clinical prognosis of patients diagnosed with colorectal cancer and their individual benefits from immunotherapy, the enhancement of the intratumoral accumulation of cytolytic effector T lymphocytes and other cellular mediators of the antitumor immune response has emerged as a targeted objective. For the future identification and clinical validation of novel therapeutic target structures, it will thus be essential to further decipher the molecular mechanisms and cellular interactions in the intestinal tumor microenvironment, which are crucially involved in immune cell recruitment and activation. In this context, our review article aims at providing an overview of the key chemokines and cytokines whose presence in the tumor micromilieu relevantly modulates the numeric composition and antitumor capacity of tumor-infiltrating lymphocytes.

Citing Articles

Dynamics of the immune microenvironment and immune cell PANoptosis in colorectal cancer: recent advances and insights.

Wan J, Zhao J, Fang X Front Immunol. 2024; 15():1502257.

PMID: 39676861 PMC: 11638180. DOI: 10.3389/fimmu.2024.1502257.


Molecular subtypes of colorectal cancer in the era of precision oncotherapy: Current inspirations and future challenges.

Dang Q, Zuo L, Hu X, Zhou Z, Chen S, Liu S Cancer Med. 2024; 13(14):e70041.

PMID: 39054866 PMC: 11272957. DOI: 10.1002/cam4.70041.


T Cells in Colorectal Cancer: Unravelling the Function of Different T Cell Subsets in the Tumor Microenvironment.

Zheng Z, Wieder T, Mauerer B, Schafer L, Kesselring R, Braumuller H Int J Mol Sci. 2023; 24(14).

PMID: 37511431 PMC: 10380781. DOI: 10.3390/ijms241411673.


Immune Response and Immune Checkpoint Molecules in Patients with Rectal Cancer Undergoing Neoadjuvant Chemoradiotherapy: A Review.

Koukourakis I, Platoni K, Tiniakos D, Kouloulias V, Zygogianni A Curr Issues Mol Biol. 2023; 45(5):4495-4517.

PMID: 37232754 PMC: 10216994. DOI: 10.3390/cimb45050285.


The Cytokine Network in Colorectal Cancer: Implications for New Treatment Strategies.

Braumuller H, Mauerer B, Andris J, Berlin C, Wieder T, Kesselring R Cells. 2023; 12(1).

PMID: 36611932 PMC: 9818504. DOI: 10.3390/cells12010138.

References
1.
Horn L, Chariou P, Gameiro S, Qin H, Iida M, Fousek K . Remodeling the tumor microenvironment via blockade of LAIR-1 and TGF-β signaling enables PD-L1-mediated tumor eradication. J Clin Invest. 2022; 132(8). PMC: 9012291. DOI: 10.1172/JCI155148. View

2.
Mlecnik B, Tosolini M, Charoentong P, Kirilovsky A, Bindea G, Berger A . Biomolecular network reconstruction identifies T-cell homing factors associated with survival in colorectal cancer. Gastroenterology. 2009; 138(4):1429-40. DOI: 10.1053/j.gastro.2009.10.057. View

3.
Perez L, Kempski J, McGee H, Pelzcar P, Agalioti T, Giannou A . TGF-β signaling in Th17 cells promotes IL-22 production and colitis-associated colon cancer. Nat Commun. 2020; 11(1):2608. PMC: 7248087. DOI: 10.1038/s41467-020-16363-w. View

4.
Sun Z, Du C, Xu P, Miao C . Surgical trauma-induced CCL18 promotes recruitment of regulatory T cells and colon cancer progression. J Cell Physiol. 2018; 234(4):4608-4616. PMC: 6585982. DOI: 10.1002/jcp.27245. View

5.
Katlinski K, Gui J, Katlinskaya Y, Ortiz A, Chakraborty R, Bhattacharya S . Inactivation of Interferon Receptor Promotes the Establishment of Immune Privileged Tumor Microenvironment. Cancer Cell. 2017; 31(2):194-207. PMC: 5313042. DOI: 10.1016/j.ccell.2017.01.004. View